Pairzon: The Portfolio's Best Asset or a Valuation Asking for Too Much Belief

Pairzon Is the Cleanest Positive Mark in the Portfolio, Which Is Exactly Why It Deserves the Hardest Test

The main article argued that Menara's discount is really about the gap between marked value and distributable cash. Pairzon is where that gap needs the sharpest follow-up. On one hand, this is the holding that looks most like a real software business rather than a purely accounting option. On the other hand, precisely because it is the portfolio's strongest positive asset, it is easy to let the valuation pass without enough scrutiny.

The operating base is real. As of the report date, Pairzon had about 90 paying customers, no single-customer concentration, an active platform in Israel plus installations in another European country and in the US, and a sales focus on the US and Europe targeting retailers with more than 100 stores. In operating terms, 2025 closed with revenue of $2.45 million, up from $1.96 million in 2024, and operating profit of NIS 1.651 million versus NIS 274 thousand a year earlier. The funding picture is also unusually orderly for a young tech company: the company reported about $800 thousand of cash, burn of about $40 thousand per month, roughly 20 months of runway, and explicitly said that since 2022 no additional equity investments had been made and that operations are being funded from customer revenue.

That is exactly why Pairzon sits at the center of the discussion. Menara's marked value in Pairzon is NIS 8.878 million, the largest single mark in the portfolio, and it still sits NIS 4.772 million above direct cost of NIS 4.106 million. The 2025 markdown was also modest, just NIS 182 thousand. If there is one asset trying to carry the optimistic side of the Menara story, this is the one.

That chart shows why Pairzon needs its own continuation. This is not just another portfolio line. It is the holding with the largest remaining value above cost, which also makes it the holding that has to carry a large part of investor trust in the portfolio.

Menara's Pairzon Value Sits on Two Model Layers, Not a Simple Revenue Multiple

The interesting part is that Menara's Pairzon mark is not a simple revenue-multiple exercise. Menara does not hold common equity. It holds two SAFE instruments, one from the initial $600 thousand investment in March 2021 and one from the additional $600 thousand SAFE in September 2022. The valuation materials also show the two contractual caps, $4 million and $5.5 million. So the path from "company value" to "Menara value" runs through an extra contractual and probabilistic layer.

The valuation works in two stages. First, Pairzon's equity value was estimated at $10.742 million, made up of $9.627 million of operating value and $1.115 million of net financial assets, using a DCF. Second, Menara's SAFE value was derived through a Monte Carlo simulation that values the conversion shares across different liquidity scenarios. The model assumes a three-year path to a liquidity event, 106% volatility, and an Equity Financing probability four times higher than a Liquidity Event probability. In the actual tables, that becomes an 80% weighting for Equity Financing + Dissolution and 20% for Liquidity Event + Dissolution.

That is a critical point for a run-off partnership. Pairzon's mark does not say a near exit is the most likely next step. It says the holding is more likely to pass through a financing event first, and only then through a liquidity event.

That chart is the real belief test. Actual 2025 ended at a 20% operating margin. But the DCF does not capitalize that margin forward. It assumes operating margin drops to about minus 62% in 2026, stays around minus 35% in 2027, and only then returns to positive territory. At the same time, revenue is supposed to move from $3.182 million in 2026 to $10.187 million in 2027, and then keep climbing to $40.065 million by 2031.

So to justify the current mark, an investor does not just need to believe Pairzon is a better business than the rest of the portfolio. They also need to believe that the relatively strong 2025 result is a transition point rather than a base, and that it will be followed by a heavy investment valley that ends in very rapid scaling. That is no longer just a debate about product quality. It is a debate about foreign-market execution, depth of commercial adoption, and how much of today's value really sits in the outer years of the model rather than in the next year or two.

There is one more cautionary layer that is easy to miss. The valuer states explicitly that the work relies on data, forecasts, and estimates provided by management, that it does not include due diligence or independent verification of those inputs, and that the cash flows should not be read as performance forecasts. That is standard language, but in Pairzon's case it matters. The more of the value sits in 2028 through 2031, the less that disclaimer is boilerplate and the more it becomes part of the economic question.

The Legal Overhang Does Not Kill the Story, but It Is Not Noise Either

Pairzon also carries a risk layer that is hard to wave away. In July 2022, a lawsuit and a request for a temporary receiver were filed against Pairzon and its founders by Wizmo Technologies, alleging use of trade secrets and intellectual property. The claim amount is NIS 2.5 million, and the plaintiff also sought injunction-style remedies tied to the alleged use of those secrets.

Legally, the story is more nuanced than the headline. The Tel Aviv Regional Labor Court did not grant the ex parte request for a temporary receiver or the temporary relief request, and later also rejected the request to preserve the status quo. The defendants denied the allegations, evidence was heard during 2024, an expert was appointed at the end of August 2024, the first expert opinion was filed in March 2025, a supplemental opinion was filed in November 2025, and the expert was cross-examined in early December 2025. As of the report date, hearing transcripts had still not been published, so the parties had not yet filed their written summations. Pairzon says, based on advice from its legal counsel, that the probability of the claim succeeding is below 50%.

This is not a simplistic "there is a lawsuit, therefore the valuation is wrong" argument. But the opposite read is too comfortable as well. For a private company that is trying to support value through a long DCF and eventually turn that value into a strategic event, an open trade-secret and IP case is exactly the sort of issue that does not need to end in a loss to affect diligence, negotiation leverage, or price.

What Pairzon Is Really Worth to Menara Right Now

The right question is not whether Pairzon looks better than Matics or Leo. On the current evidence, it does. The right question is whether it can already be treated as a monetization anchor rather than just a valuation anchor. At year-end 2025, the answer is still cautious.

Pairzon probably is the best operating asset left in Menara. It has paying customers, no single-customer dependence, customer-funded operations, a 2025 result that looks like real business progress rather than pure promise, and a fair value still meaningfully above cost. But the number that matters to Menara, NIS 8.878 million, asks the reader to underwrite four layers at once: that US and European expansion will work, that the 2026 to 2027 operating valley will lead to scale rather than to a weak financing round, that the SAFE structure will capture the upside as intended, and that the legal case will not weigh on the company when the real test arrives.

What would make that value look less like belief and more like an anchor:

• Pairzon needs to show that the jump built into 2026 and 2027 is turning into real orders and real revenue, not just into planning language.
• If a financing event arrives, it needs to strengthen the path to liquidity rather than reveal that Equity Financing was effectively the destination rather than a waypoint.
• The legal process needs to move toward lower uncertainty before a strategic event, rather than still being open at the exact point when external validation is needed.

The conclusion is fairly sharp. Pairzon can be the best asset in Menara's portfolio and still be a valuation asking for too much belief. In a run-off vehicle, that is not a semantic distinction. It is the difference between an asset that looks good on paper and one that can turn into cash on a reasonable timetable.